KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Critical reviews in oncology/hematology
- Publicado em
- 22 abr 2025
- Citações
- 5
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials
Erman Akkus, Nejat Emre Öksüz, Enes Erul
Descritores MeSH
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Colorectal Neoplasms
- Proto-Oncogene Proteins p21(ras)
- Neoplasm Metastasis
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Treatment Outcome
- Clinical Trials, Phase I as Topic
- Humans
Veja também
Estudos relacionados
- A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science
- Evaluation of fruquintinib's efficacy and safety in refractory metastatic colorectal cancer: a systematic review and meta-analysis of phase II and III randomized controlled trials
- Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial
- Eficácia e segurança comparativas de regimes alvo de BRAF de segunda e última linha no câncer colorretal metastático com mutação BRAF V600E: Uma revisão sistemática e meta-análise em rede